Literature DB >> 12619120

Absence of exon 15 BRAF germline mutations in familial melanoma.

Julie Lang1, Maureen Boxer, Rona MacKie.   

Abstract

We have analyzed DNA from peripheral blood of 42 cases of familial melanoma for germline mutations in exon 15 of the BRAF gene. No evidence of mutation was found. We have also analyzed DNA extracted from secondary melanoma from two members of these families. These results were also negative. In addition we have searched for exon 15 BRAF mutations in 24 samples of secondary melanoma from 22 cases of sporadic melanoma and detected the 1796T>A BRAF mutation which leads to a substitution of valine by glutamic acid at position 599 (V599E) in six samples. Peripheral blood DNA from two of these tumor-positive cases of sporadic melanoma were negative for the V599E BRAF mutation. This mutation therefore appears to be a somatic mutation associated with melanoma development and/or progression in a proportion of affected individuals. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12619120     DOI: 10.1002/humu.10188

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  10 in total

1.  Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases.

Authors:  Arati Sharma; Melissa A Tran; Shile Liang; Arun K Sharma; Shantu Amin; Charles D Smith; Cheng Dong; Gavin P Robertson
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

2.  Genetics and genomics of melanoma.

Authors:  Papia Ghosh; Lynda Chin
Journal:  Expert Rev Dermatol       Date:  2009-04-01

3.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

4.  Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.

Authors:  Jinming Yang; Snjezana Zaja-Milatovic; Yee-Mon Thu; Francis Lee; Richard Smykla; Ann Richmond
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

5.  Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas.

Authors:  Caroline Kannengiesser; Alain Spatz; Stefan Michiels; Alain Eychène; Philippe Dessen; Vladimir Lazar; Véronique Winnepenninckx; Fabienne Lesueur; Sabine Druillennec; Caroline Robert; Joost J van den Oord; Alain Sarasin; Brigitte Bressac-de Paillerets
Journal:  Mol Oncol       Date:  2008-01-12       Impact factor: 6.603

6.  Characterization of Ser338 phosphorylation for Raf-1 activation.

Authors:  Mengwei Zang; Jun Gong; Lingqi Luo; Jing Zhou; Xiaoqin Xiang; Wei Huang; Qiren Huang; Xixi Luo; Martin Olbrot; Yihong Peng; Changyan Chen; Zhijun Luo
Journal:  J Biol Chem       Date:  2008-09-05       Impact factor: 5.157

7.  Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women.

Authors:  Yun-Hyun Cho; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Kyu-Rae Kim; Joo-Hyun Nam; Young-Tak Kim
Journal:  Yonsei Med J       Date:  2009-04-30       Impact factor: 2.759

8.  Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.

Authors:  Roland Houben; Jürgen C Becker; Andreas Kappel; Patrick Terheyden; Eva-B Bröcker; Rudolf Goetz; Ulf R Rapp
Journal:  J Carcinog       Date:  2004-03-26

9.  Polymorphisms of the BRAF gene predispose males to malignant melanoma.

Authors:  Peter Meyer; Consolato Sergi; Claus Garbe
Journal:  J Carcinog       Date:  2003-11-14

10.  Essential genes in thyroid cancers: focus on fascin.

Authors:  Hilda Samimi; Majid Zaki Dizaji; Mohsen Ghadami; Abolhasan Shahzadeh Fazeli; Patricia Khashayar; Masoud Soleimani; Bagher Larijani; Vahid Haghpanah
Journal:  J Diabetes Metab Disord       Date:  2013-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.